Answers are grounded in this paper and cite their sources.
Intralesional methotrexate achieves 62% tumour shrinkage in facial cutaneous squamous cell carcinoma, suggesting its role as a low-cost adjunct therapy.
Intralesional methotrexate was used to achieve significant tumour shrinkage in a large facial cutaneous squamous cell carcinoma, resulting in a 62% reduction in size and clearer margin definition. This case highlights methotrexate’s potential as a simple, low-cost preoperative adjunct for complex cSCC.
No takes yet. Share an insight, caveat, or question.
R. Mallipeddi (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: